XTNT · Xtant Medical Holdings, Inc.

Xtant Medical Holdings has significantly expanded its commercial footprint through a strategic distribution agreement with Dilon Technologies. By securing exclusive U.S. rights to HEMOBLAST Bellows, an FDA-approved surgical hemostatic agent, Xtant broadens its product portfolio beyond spinal and orthopedic conditions into the broader surgical hemostasis market. The transaction involves an upfront cash commitment of $5.0 million for exclusivity, which carries some protection for Xtant as the fee is repayable under certain termination clauses. A critical operational component of the deal is the immediate integration of approximately 20 experienced sales personnel from Dilon, which management believes will enhance Xtant's commercial capabilities and reach. The agreement structure is favorable regarding inventory risk, as it contains no minimum purchase requirements, and Dilon retains manufacturing responsibilities in France. This arrangement allows Xtant to focus on distribution while leveraging Dilon's existing manufacturing infrastructure. Furthermore, the transition of the existing U.S. customer base and contracts provides an immediate revenue stream. Investors should anticipate an update to the company's full-year 2026 financial guidance when first-quarter results are released, reflecting the impact of this new distribution arrangement.